MARKET

SPRB

SPRB

Spruce Biosciences, Inc.
NASDAQ
46.20
-0.67
-1.43%
Closed 19:34 08/10 EDT
OPEN
46.69
PREV CLOSE
46.87
HIGH
46.69
LOW
45.01
VOLUME
35.63K
TURNOVER
517.71K
52 WEEK HIGH
240.00
52 WEEK LOW
7.00
MARKET CAP
127.16M
P/E (TTM)
-1.2061
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SPRB last week (0803-0807)?
Weekly Report · 1d ago
Spruce Biosciences appoints Jessica Cohen Pfeffer as VP, clinical development
TipRanks · 08/03 12:17
Weekly Report: what happened at SPRB last week (0727-0731)?
Weekly Report · 08/03 09:28
Spruce Biosciences Moves Tralesinidase Alfa Into Phase 3, Putting Rare Disease Upside in Focus
TipRanks · 07/30 16:32
Weekly Report: what happened at SPRB last week (0720-0724)?
Weekly Report · 07/27 09:30
Weekly Report: what happened at SPRB last week (0713-0717)?
Weekly Report · 07/20 09:28
American Express, Biogen upgraded: Wall Street’s top analyst calls
TipRanks · 07/13 13:45
Spruce Biosciences Price Target Announced at $160.00/Share by B. Riley Securities
Dow Jones · 07/13 13:18
More
About SPRB
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. It has a diverse portfolio of product candidates addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options. Its pipeline consists of TA-ERT, Tildacerfont and Cortibon, and SPR202. TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. Tildacerfont has the potential to address hyperactive brain corticotropin-releasing factors neurotransmission and aberrant functioning of the hypothalamus-pituitary-adrenal axis in patients with MDD. SPR202 focuses on the treatment of Congenital Adrenal Hyperplasia and other indications.

Webull offers Spruce Biosciences, Inc stock information, including NASDAQ: SPRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPRB stock methods without spending real money on the virtual paper trading platform.